Caffeine intake as a protective factor in the development and progression of Parkinson's disease and Alzheimer's disease: an integrative review
DOI:
https://doi.org/10.33448/rsd-v11i8.31424Keywords:
Caffeine; Alzheimer's Disease; Parkinson's Disease; Neuroprotection; Neurodegeneration.Abstract
Introduction: The prevalence of Alzheimer's disease (AD) and Parkinson's disease (PD) tends to increase with the aging population. Currently, the therapeutic schemes for these diseases cannot achieve a cure and are also not frequently updated, which highlights the need for other options to improve the quality of life of these patients. Given that these dementia syndromes have a multifactorial etiology, diet, through coffee, has shown significant evidence in neuronal degeneration, which is one of the main aspects altered in the development of these pathologies. Methodology: This is an integrative review, which sought to answer what the possible effects of caffeine as a protective factor in the development and progression of AD and PD, in the databases: Virtual Health Library (VHL) National Library of Medicine (PubMed MEDLINE) and Scientific Electronic Library Online (Scielo). Results and Discussion: Caffeine acts in the central nervous system (CNS) by mimicking the adenosine receptors, more concentrated in the A1R and A2aR receptors. As a competitive antagonist, caffeine could possibly reduce the processes of b-amyloid plaque formation in AD and reduce neuroinflammation and neurodegeneration in PD, besides other possible mechanisms. Conclusion: The delimitation of a consensus on the dose/effect relation resulting from the use of caffeine is difficult to establish and a consensus is not yet observed; however, it is possible to observe that an intake between 200mg to 511mg per day could bring beneficial effects both in PD and in AD, overcoming the possible side effects.
References
Brasil, M. S. (2022). Ministério da Saúde RENAME: Relação Nacional de Medicamentos Essenciais 2022. Biblioteca Virtual em Saúde do Ministério da Saúde. https://www.conass.org.br/wp-content/uploads/2022/01/RENAME-2022.pdf
Carman, A. J., Dacks, P. A., Lane, R. F., Shineman, D. W., & Fillit, H. M. (2014). Current evidence for the use of coffee and caffeine to prevent age-related cognitive decline and Alzheimer's disease. The journal of nutrition, health & aging, 18(4), 383–392.
Chan, L., Hong, C. T., & Bai, C. H. (2021). Coffee consumption and the risk of cerebrovascular disease: a meta-analysis of prospective cohort studies. BMC neurology, 21(1), 380.
Dall'Igna, O. P., Porciúncula, L. O., Souza, D. O., Cunha, R. A., & Lara, D. R. (2003). Neuroprotection by caffeine and adenosine A2A receptor blockade of beta-amyloid neurotoxicity. British journal of pharmacology, 138(7), 1207–1209.
Eskelinen, M. H., Ngandu, T., Tuomilehto, J., Soininen, H., & Kivipelto, M. (2009). Midlife coffee and tea drinking and the risk of late-life dementia: a population-based CAIDE study. Journal of Alzheimer's disease: JAD, 16(1), 85–91.
Feter, N., Leite, J. S., Caputo, L. E., Cardoso, K. R., & Rombaldi, J. A. (2021). Who are the people with Alzhermer’s disease in Brazil? Findings from the Brazilian Longitudinl Study of Aging. Revista Brasileira de Epidemiologia, 24.
Halldner, L., Adén, U., Dahlberg, V., Johansson, B., Ledent, C., & Fredholm, B. B. (2004). The adenosine A1 receptor contributes to the stimulatory, but not the inhibitory effect of caffeine on locomotion: a study in mice lacking adenosine A1 and/or A2A receptors. Neuropharmacology, 46(7), 1008–1017.
Hong, C. T., Chan, L., & Bai, C. H. (2020). The Effect of Caffeine on the Risk and Progression of Parkinson's Disease: A Meta-Analysis. Nutrients, 12(6), 1860.
Iqbal, K., Liu, F., Gong, C. X., & Grundke-Iqbal, I. (2010). Tau in Alzheimer disease and related tauopathies. Current Alzheimer research, 7(8), 656–664.
Kolahdouzan, M., & Hamadeh, M. J. (2017). The neuroprotective effects of caffeine in neurodegenerative diseases. CNS neuroscience & therapeutics, 23(4), 272–290.
Londzin, P., Zamora, M., Kąkol, B., Taborek, A., & Folwarczna, J. (2021). Potential of Caffeine in Alzheimer's Disease-A Review of Experimental Studies. Nutrients, 13(2), 537.
Lopes, C. R., Cunha, R. A., & Agostinho, P. (2021). Astrocytes and Adenosine A2A Receptors: Active Players in Alzheimer's Disease. Frontiers in neuroscience, 15, 666710.
Mohamed, R. A., Agha, A. M., Abdel-Rahman, A. A., & Nassar, N. N. (2016). Role of adenosine A2A receptor in cerebral ischemia reperfusion injury: Signaling to phosphorylated extracellular signal-regulated protein kinase (pERK1/2). Neuroscience, 314, 145–159.
Nehlig A. (2016). Effects of coffee/caffeine on brain health and disease: What should I tell my patients?. Practical neurology, 16(2), 89–95.
Norwitz, N. G., Saif, N., Ariza, I. E., & Isaacson, R. S. (2021). Precision Nutrition for Alzheimer's Prevention in ApoE4 Carriers. Nutrients, 13(4), 1362.
Panza, F., Solfrizzi, V., Barulli, M. R., Bonfiglio, C., Guerra, V., Osella, A., Seripa, D., Sabbà, C., Pilotto, A., & Logroscino, G. (2015). Coffee, tea, and caffeine consumption and prevention of late-life cognitive decline and dementia: a systematic review. The journal of nutrition, health & aging, 19(3), 313–328.
Santos, G. F., Silva, G. d. Q. N. e., Moreira, D. R., Vergutz, B. G., Carvalho, J. P. d. M., Pessoa, J. P. A., Tafuri, N. F. (2022). Doença de Parkinson: Padrão epidemiológico de internações no Brasil. Research, Society and Development, 11(1).
Schepici, G., Silvestro, S., Bramanti, P., & Mazzon, E. (2020). Caffeine: An Overview of Its Beneficial Effects in Experimental Models and Clinical Trials of Parkinson's Disease. International journal of molecular sciences, 21(13), 4766.
Souza, C. F. M., Almeida, H. C. P., Sousa, J. B., Costa, P. H., Silveira, Y. S. S., & Bezerra, J. C. L. (2011). A Doença de Parkinson e o Processo de Envelhecimento Motor: Uma Revisão de Literatura. Revista Neurociências, 19(4), 718–723.
Teo, K. C., & Ho, S. L. (2013). Monoamine oxidase-B (MAO-B) inhibitors: implications for disease-modification in Parkinson's disease. Translational neurodegeneration, 2(1), 19.
Zhou, Z. D., Xie, S. P., Saw, W. T., Ho, P., Wang, H., Lei, Z., Yi, Z., & Tan, E. K. (2019). The Therapeutic Implications of Tea Polyphenols Against Dopamine (DA) Neuron Degeneration in Parkinson's Disease (PD). Cells, 8(8), 911.
Zhou, X., & Zhang, L. (2021). The Neuroprotective Effects of Moderate and Regular Caffeine Consumption in Alzheimer's Disease. Oxidative medicine and cellular longevity, 2021, 5568011.
Souza, M. T., Silva, M. D., Carvalho, R. (2010). Revisão integrativa: oque é e como fazer. Einstein, 8(1), 102-106.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Tatiana Lima Paiva; Giovanni Ferreira Santos; João Otávio Bayão Coutinho; Mariana Moreira Munhoz Mendonça; Dalbert Samuel Dutra; Jorge Antonio de Moura Leite; José Marcos Leite Rigueira; Giulia Pieroli Mazzieiro; Louvana Cristelle Camargos Ferreira; Bethânia Cristhine de Araújo
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
